Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

This GLP-1 Is the Most Effective for Weight Loss, Study Says

A new study says that people who use tirzepatide lose more weight than people who use semaglutide Getty Stock image of a woman weighing herself.Tirzepatide is more effective than semaglutide for weight loss, according to a new study on GLP-1 medications The study was funded by Eli Lilly, the pharmaceutical company that manufactures tirzepatide, so "take that with a grain of salt," one expert saidTirzepatide, which reduces appetite and improves h…

PODCAST: CFRA's House Calls for Sun. May 11th, 2025

Eli Lilly has plastered a 'fat tax' on the Canadian market for their weight loss drug. Dr. Yoni Freedhoff joins the program with his reaction. Then, Dr. Dworkin opens the phone lines and reads your texts.

Why Obesity Drugs Are Getting Cheaper — and Also More Expensive

Pricing and insurance coverage are in flux, and new research gives an edge to Eli Lilly’s Zepbound.

Eli Lilly Vs. Novo Nordisk: Which Pharma Stock Is Likely to Do Better in 2025?

Market Analysis by covering: Eli Lilly and Company, Novo Nordisk A/S. Read 's Market Analysis on Investing.com

Study: Zepbound beats Wegovy for weight loss

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.

Study: Zepbound beats Wegovy for weight loss in head-to-head test

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.